Sign up
Log in
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $6K Worth of Abbott Laboratories Stock
Share
Listen to the news

A August filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories (NYSE:ABT), valued between $6,006 and $90,000. The transaction date is listed as July 18, 2025, with the report published on August 11, 2025.

At present, Abbott Laboratories shares are trading down 1.0% at $130.04.

Stay informed on Josh Gottheimer's trades and other members of Congress with our real-time government trades tracking tool!

The Importance of Congressional Transactions

A congressional transaction is when any representative or senator either buys or sells an individual stock.

Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.

In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.

The Importance of Congressional Transactions

Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.

When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.

A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.